Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Silo Pharma Inc (SILO)
Silo Pharma Inc (SILO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,819
  • Shares Outstanding, K 3,109
  • Annual Sales, $ 70 K
  • Annual Income, $ -3,910 K
  • 60-Month Beta -0.38
  • Price/Sales 68.12
  • Price/Cash Flow N/A
  • Price/Book 0.69
Trade SILO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +16.94%
on 11/16/23
1.9800 -26.77%
on 11/21/23
-0.0101 (-0.69%)
since 11/01/23
3-Month
1.2162 +19.22%
on 10/16/23
2.0800 -30.29%
on 09/06/23
-0.5700 (-28.22%)
since 09/01/23
52-Week
1.2162 +19.22%
on 10/16/23
6.5600 -77.90%
on 12/30/22
-2.0500 (-58.57%)
since 12/01/22

Most Recent Stories

More News
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.085 (-1.16%)
SILO : 1.4500 (-6.45%)
LLY : 584.04 (-1.18%)
ACOR : 10.32 (+5.29%)
TRVN : 0.5850 (+0.55%)
IMRN : 2.05 (-3.30%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 1.4500 (-6.45%)
LLY : 584.04 (-1.18%)
ACOR : 10.32 (+5.29%)
TRVN : 0.5850 (+0.55%)
IMRN : 2.05 (-3.30%)
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

ENGLEWOOD CLIFFS, NJ – May 9,  2023 – Silo Pharma, Inc.  (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 1.4500 (-6.45%)
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc.  (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 1.4500 (-6.45%)
Silo Pharma (NASDAQ: SILO) Provides Update on Study of Ketamine Formulations for Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive...

SILO : 1.4500 (-6.45%)
Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent...

SILO : 1.4500 (-6.45%)
Silo Pharma (NASDAQ: SILO) to Benefit as Study Supports Psychedelics in Treating Depression

In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than...

SILO : 1.4500 (-6.45%)
Silo Pharma (NASDAQ: SILO) Expands IP, Tech Rights for Treating Rare Stress-Related Conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15...

SILO : 1.4500 (-6.45%)
Silo Pharma (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”)...

SILO : 1.4500 (-6.45%)
Silo Pharma (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office...

SILO : 1.4500 (-6.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer's, and other rare neurological disorders. Silo Pharma. Inc. is based in ENGLEWOOD CLIFFS, NJ.

See More

Key Turning Points

3rd Resistance Point 1.5767
2nd Resistance Point 1.5433
1st Resistance Point 1.4967
Last Price 1.4500
1st Support Level 1.4167
2nd Support Level 1.3833
3rd Support Level 1.3367

See More

52-Week High 6.5600
Fibonacci 61.8% 4.5187
Fibonacci 50% 3.8881
Fibonacci 38.2% 3.2575
Last Price 1.4500
52-Week Low 1.2162

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar